CellCentric
BiotechnologyView the employees at
CellCentric-
Jessica Verlinden Chartered Accountant
-
Peterborough, England, United Kingdom
-
Rising Star
Thea Stanway Finance Director at CELLCENTRIC LIMITED-
Little Chesterford
-
Rising Star
Oliver Hook SCRA at Freelance Position with Quintiles-
Top 10%
Kris Frese Director of Cancer Biology-
Manchester
-
Top 5%
Ruth Tysoe Contract Clinical Research Associate at CELLCENTRIC LIMITED-
Greater Cambridge Area
-
Top 10%
Overview
Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.
-